FDA ad­comm votes in fa­vor of Al­ny­lam's new in­di­ca­tion for On­pat­tro

The FDA’s Car­dio­vas­cu­lar and Re­nal Drugs Ad­vi­so­ry Com­mit­tee on Wednes­day vot­ed 9-3 in fa­vor of Al­ny­lam Phar­ma­ceu­ti­cals’ On­pat­tro (patisir­an) on whether its ben­e­fits out­weigh its risks for the treat­ment of AT­TR car­diomy­opa­thy.

Pan­elists agreed that the mag­ni­tude of On­pat­tro’s ben­e­fit in this in­di­ca­tion was small, but the risks were even small­er.

Ad­comm mem­ber Ed­ward Kasper of Johns Hop­kins School of Med­i­cine said he based his “yes” vote on the fact there’s a “light wind” for ben­e­fit and “no wind” for risk. David Cel­la, pro­fes­sor at North­west­ern Uni­ver­si­ty Fein­berg School of Med­i­cine, al­so vot­ed in fa­vor and not­ed lim­it­ed ben­e­fits but said that he hopes clin­i­cians will coun­sel pa­tients on this op­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER